Impel NeuroPharma, fresh off IPO, gets FDA approval for nasal spray that treats migraines
Impel NeuroPharma announced Trudhesa, a drug used to treat migraines, has officially received approval from the U.S. Food and Drug Administration.
John Hoekman originally co-founded the company in 2008 as a graduate student at the University of Washington and is now the chief technology and development officer.
The Seattle-based biotech company said the drug will be launched for commercial sales in October. The new medication may help the 31 million adults in the U.S. who are living with migraines.